Adherence problems in elderly patients with hypertension

Pobrotyn, Piotr; Chudiak, Anna; Uchmanowicz, Bartosz; Drobnik, Jarosław; Gajda, Robert

doi:10.5603/mrj.a2023.0004

Cited by 3 publications

(5 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previously, greater reductions of both HbA1c and body weight at higher baseline values were observed [60,62,63], therefore even greater mean reduction of these parameters should be expected in patients with a diagnosis of obesity and metabolic syndrome than in the population of patients with T2 diabetes, only some of whom met the definition of obesity. Moreover, the dose-dependent effect of empagliflozin regarding these variables was reported [60].…”

Section: Discussionmentioning

confidence: 92%

See 1 more Smart Citation

Efficacy of double vs. standard empagliflozin dose for METabolic syndromE tReatment (DEMETER — SIRIO 11) study. Rationale and protocol of the study

Kubica,

Grąbczewska

et al. 2023

Medical Research Journal

View full text Add to dashboard Cite

Complex metabolic disorders associated with obesity and diabetes pose a serious therapeutic challenge.The DEMETER-SIRIO 11 study is a phase III, multicenter, randomized, open-label, investigator-initiated clinical trial with a 6-month follow-up aimed at performing a comparative evaluation of the effect of two empagliflozin doses (10 mg vs. 20 mg) on selected metabolic parameters in patients with metabolic syndrome. The primary hypothesis of the study is that a higher dose of empagliflozin will result in a significant reduction of BMI and HbA1c in patients with obesity and MS receiving empagliflozin 20 mg as compared to 10 mg. Sample size and power calculation were based on a superiority assumption for the primary efficacy endpoint (the difference in decrease of body weight by > 1.5 kg and HbA1c by > 0.4%) for the higher vs.standard dose arm at 6-months of follow-up. Therefore, a sample size of 79 patients per arm is required to provide 80% power to detect a higher decrease in BMI, and 85 patients per arm is required to provide 80% power to detect a higher decrease in HbA1c in the 20 mg versus 10 mg arm with a type I error rate of 0.05. Summing up, enrollment of a total of 200 patients (100 in each arm) is planned to compensate for the potential drop-out rate from the study of up to 15%. Prespecified subanalyses will be performed according to: 1) diabetes mellitus; 2) chronic kidney disease (GFR < 60 mL/min/1.73 m 2 ); 3) gender; and 4) age.A greater comprehensive improvement in biochemical, functional, and anthropometric parameters reflecting favorable metabolic changes is expected at the higher dose of empagliflozin compared to the standard dose.

show abstract

Section: Discussionmentioning

confidence: 92%

“…Moreover, the dose-dependent effect of empagliflozin regarding these variables was reported [60]. Weight reduction has been shown to improve weight-related quality of life and satisfaction with physical and emotional health [63]. This effect is expected to improve adherence to the investigated treatment [64][65][66][67][68][69][70].…”

Section: Discussionmentioning

confidence: 99%

Efficacy of double vs. standard empagliflozin dose for METabolic syndromE tReatment (DEMETER — SIRIO 11) study. Rationale and protocol of the study

Kubica,

Grąbczewska

et al. 2023

Medical Research Journal

View full text Add to dashboard Cite

show abstract

“…There are multiple patient-related causes leading to poor adherence associated with old age, including decreased quality of life, low mood and presence of depressive symptoms, and clinical and sociodemographic factors. Recently Pobrotyn et al published in the Medical Research Journal the results of a prospective cross-sectional study assessing adherence problems in 100 elderly patients with hypertension [7]. They observed a relatively high proportion of patients with a high level of adherence (63%) and a very low incidence of low adherence (3%) as assessed with the Adherence in Chronic Disease Scale (ACDS).…”

Section: To the Editormentioning

confidence: 99%

Adherence to medication in elderly patients

Kubica

2023

Medical Research Journal

View full text Add to dashboard Cite

show abstract

“…According to the literature, medication adherence can affect the therapeutic and clinical outcome, as well as health-related quality of life ( 3 , 7 , 8 ). Medication non-adherence is a major global health problem with significant consequences in older adults due to their chronic and multiple diseases and polypharmacy ( 9 , 10 ). Patients with high blood pressure are unaware of the progress of the disease and its potential damage to various organs of the body if they do not adhere to the treatment ( 5 , 11 , 12 ).…”

Section: Introductionmentioning

confidence: 99%

“…Health literacy has a positive and strong relationship with medication adherence ( 18 ). Despite decades of research in medication adherence, non-adherence to treatment in patients aged over 65 years with blood pressure is still controversial ( 9 ). Considering the importance of medication adherence in older adults’ health, the present study aimed to identify the determinants of medication adherence among older patients with hypertension.…”

Section: Introductionmentioning

confidence: 99%

Impact of health literacy and illness perception on medication adherence among older adults with hypertension in Iran: a cross-sectional study

Babazadeh,

Ranjbaran,

Pourrazavi

et al. 2024

Front. Public Health

View full text Add to dashboard Cite

BackgroundAdherence to medication is an essential factor in controlling and reducing the side effects of non-communicable diseases, particularly hypertension. Medication adherence varies in older adults due to the effects of various factors. The research aimed to examine the determinants of medication adherence among older adults with hypertension.MethodsThis cross-sectional study was performed among 300 people aged 60 years or older referring to health centers in Sarab, Iran, between February and May 2023. To collect data, valid and reliable tools were applied.ResultsThere was a significant association between age groups, level of education, and monthly income status with adherence to medication (p-value <0.05). According to the results of hierarchical regression, demographic variables collectively explained 3.2% of the variance in adherence to therapeutic regimens (p-value = 0.143). The inclusion of illness perception at step 2, along with demographic variables, led to a further significant increase in 9.6% of the variance (p-value <0.001). In the final step, health literacy dimensions were added, which explained an additional 8.7% of the variance (p-value <0.001). In total, demographic variables, illness perception, and HL dimensions explained 21.5% of the variance in adherence to therapeutic regimens.ConclusionAccording to the results, demographic variables, illness perception, and HL dimensions were the main determinants of medication adherence among older adults. Health educators should focus on creating interventions that improve medication adherence by addressing illness perception and health literacy dimensions in this particular population.

show abstract

Adherence problems in elderly patients with hypertension

Abstract: This article has been peer reviewed and published immediately upon acceptance.It is an open access article, which means that it can be downloaded, printed, and distributed freely, provided the work is properly cited.

Cited by 3 publications

References 23 publications

Efficacy of double vs. standard empagliflozin dose for METabolic syndromE tReatment (DEMETER — SIRIO 11) study. Rationale and protocol of the study

Efficacy of double vs. standard empagliflozin dose for METabolic syndromE tReatment (DEMETER — SIRIO 11) study. Rationale and protocol of the study

Adherence to medication in elderly patients

Impact of health literacy and illness perception on medication adherence among older adults with hypertension in Iran: a cross-sectional study

Contact Info

Product

Resources

About